

**Synonym**

LILRA4,CD85g,ILT7,ILT-7

**Source**

Human LILRA4 Protein, His Tag(LI4-H52H5) is expressed from human 293 cells (HEK293). It contains AA Glu 24 - Asn 446 (Accession # [P59901-1](#)).

Predicted N-terminus: Glu 24

**Molecular Characterization**

LILRA4(Glu 24 - Asn 446)  
P59901-1 Poly-his

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 48.5 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

**Endotoxin**

Less than 1.0 EU per  $\mu\text{g}$  by the LAL method.

**Purity**

>90% as determined by SDS-PAGE.

**Formulation**

Lyophilized from 0.22  $\mu\text{m}$  filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*


**Storage**

For long term storage, the product should be stored at lyophilized state at  $-20^{\circ}\text{C}$  or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:


- $-20^{\circ}\text{C}$  to  $-70^{\circ}\text{C}$  for 12 months in lyophilized state;
- $-70^{\circ}\text{C}$  for 3 months under sterile conditions after reconstitution.

**SDS-PAGE**

Human LILRA4 Protein, His Tag on SDS-PAGE under reducing (R) condition.

The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

**Bioactivity-ELISA**



Immobilized Human LILRA4 Protein, His Tag (Cat. No. LI4-H52H5) at 2 µg/mL (100 µL/well) can bind Monoclonal Anti-LILRA4 Antibody, Human IgG1 with a linear range of 0.001-0.063 µg/mL (QC tested).

## Background

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFN $\alpha$  associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFN $\alpha$ -producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFN $\alpha$  which drives autoimmune disease symptoms.

## Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.